ZURICH, July 23 (Reuters) - The European Union has given a positive opinion on Roche Holding AG’s ROG.VX flu drug Tamiflu in small capsules, the Swiss drugmaker said on Monday, a step normally followed by marketing approval.
The EU’s Committee of Human Medicinal Products had recommended marketing authorisation for Tamiflu in capsules of 30 mg and 45 mg doses, largely for use by children.
Roche said it had recently received approval for Tamiflu -- which countries across the world have stockpiled to fight a possible bird flu pandemic -- in lower doses in the United States.
The smaller capsules could also be used by the elderly or by adults having difficulty swallowing big capsules.
Recommendations for marketing approval by the committee are normally endorsed by the European Commission with a few months.
((Reporting by Douwe Miedema
Editing by David Holmes
Telephone: +41 (0)44 631 7354)) Keywords: ROCHE TAMIFLU/
C Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nL23610724